Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Jazz Pharma Plc (NQ: JAZZ ) 101.07 +0.50 (+0.50%) Streaming Delayed Price Updated: 11:40 AM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Jazz Pharma Plc < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling November 21, 2022 Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent. Via Benzinga Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent November 21, 2022 Via Benzinga Got $500? 3 Growth Stocks to Buy That Could Double Your Money November 20, 2022 Innovative products and services could keep these companies growing. Via The Motley Fool 3 Top Cannabis Stocks to Buy in November November 20, 2022 These solid performers are managing to grow revenue in a difficult environment. Via The Motley Fool 2 Dirt Cheap Growth Stocks to Buy and Hold for Years November 18, 2022 In the long run, these stocks could deliver great returns. Via The Motley Fool Is Axsome Therapeutics Stock a Buy Now? November 11, 2022 The company seems to be coming into its own. Via The Motley Fool Why Shares of Zymeworks Rose 12.18% on Monday October 31, 2022 The biotech stock's shares may have been pushed by a short squeeze. Via The Motley Fool Why Zymeworks Stock Is Soaring Today October 19, 2022 Investors applauded a major licensing deal with Jazz Pharmaceuticals. Via The Motley Fool Jazz Pharmaceuticals' Return On Capital Employed Insights August 08, 2022 Via Benzinga What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals November 10, 2022 Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: Via Benzinga Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance November 10, 2022 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. Via Benzinga Why Axsome Therapeutics Stock Slipped Today November 07, 2022 Investors traded out of the company following the latest earnings release, but only to a modest degree. Via The Motley Fool 3 Top Healthcare Stocks to Buy for November November 04, 2022 Catalysts lie ahead for these promising stocks. Via The Motley Fool 2 Marijuana Stocks That Are Set for a Comeback October 28, 2022 Don't overlook these top stocks when investing in the marijuana space. Via The Motley Fool Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval October 26, 2022 A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals... Via Benzinga Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline October 21, 2022 Via Benzinga Why Is Zymeworks (ZYME) Stock Up Today? October 19, 2022 Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ). Via InvestorPlace Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal October 19, 2022 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session October 18, 2022 This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... Via Benzinga 2 Biotech Stocks You Can Buy and Hold for the Next Decade October 18, 2022 These two durable companies can navigate the market downturn and beyond. Via The Motley Fool 3 Red-Hot Stocks That Could Continue to Beat the Market October 13, 2022 Investors are betting on these companies' revenue growth prospects. Via The Motley Fool 3 Top Marijuana Stocks to Buy for the Long Haul October 07, 2022 The three have the financial strength to benefit from increased cannabis sales and cannabis therapies. Via The Motley Fool 3 Stocks Savvy Investors Are Buying Hand Over Fist October 06, 2022 These high-flying stocks are defying the bear market. Via The Motley Fool Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit September 29, 2022 A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision... Via Benzinga UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar September 29, 2022 Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading. Via Benzinga 5 Analysts Have This to Say About Jazz Pharmaceuticals September 21, 2022 Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Via Benzinga 7 Top-Rated Biotech Stocks to Buy for Q4 September 15, 2022 A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. Via InvestorPlace The Bright Future Of Cannabis Isn’t In Dispensaries - It’s In The Biotech Lab August 29, 2022 Cannabis businesses offer a lucrative opportunity for investors, but one sector in particular represents untapped potential: cannabinoid pharmaceuticals. Via Talk Markets Recap Of Thursday's Biotech Catalysts - End Of the Day Summary August 18, 2022 Via Benzinga Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures August 18, 2022 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents... Via Benzinga < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.